Sarah Aebersold Sells 2,695 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 2,695 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $25.44, for a total transaction of $68,560.80. Following the completion of the transaction, the insider now owns 43,165 shares in the company, valued at approximately $1,098,117.60. This trade represents a 5.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Sarah Aebersold also recently made the following trade(s):

• On Friday, March 14th, Sarah Aebersold sold 5,632 shares of BioLife Solutions stock. The shares were sold at an average price of $24.96, for a total transaction of $140,574.72.
• On Tuesday, March 11th, Sarah Aebersold sold 1,091 shares of BioLife Solutions stock. The shares were sold at an average price of $25.00, for a total transaction of $27,275.00.
• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total transaction of $6,484.80.

BioLife Solutions Price Performance

Shares of NASDAQ:BLFS opened at $25.48 on Thursday. BioLife Solutions, Inc. has a 1-year low of $14.84 and a 1-year high of $29.55. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The business has a fifty day moving average price of $26.48 and a 200-day moving average price of $25.49. The company has a market capitalization of $1.20 billion, a PE ratio of -24.04 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The firm had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. During the same period last year, the company earned ($0.21) earnings per share. As a group, equities analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on BLFS shares. Northland Securities increased their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday, January 8th. StockNews.com raised BioLife Solutions from a “sell” rating to a “hold” rating in a research note on Wednesday. HC Wainwright increased their price objective on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. KeyCorp raised their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Finally, Benchmark reaffirmed a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research note on Thursday, December 19th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, BioLife Solutions currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.86.

Institutional Investors Weigh In On BioLife Solutions

Several large investors have recently bought and sold shares of the business. Invesco Ltd. increased its holdings in BioLife Solutions by 1.1% in the 4th quarter. Invesco Ltd. now owns 3,239,469 shares of the medical equipment provider’s stock worth $84,097,000 after buying an additional 36,176 shares in the last quarter. Fred Alger Management LLC increased its holdings in BioLife Solutions by 1.0% in the 4th quarter. Fred Alger Management LLC now owns 1,594,221 shares of the medical equipment provider’s stock worth $41,386,000 after buying an additional 16,274 shares in the last quarter. State Street Corp increased its holdings in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after buying an additional 95,788 shares in the last quarter. Millennium Management LLC increased its holdings in BioLife Solutions by 49.1% in the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock worth $29,733,000 after buying an additional 377,111 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in BioLife Solutions by 4.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 887,008 shares of the medical equipment provider’s stock worth $23,028,000 after buying an additional 40,416 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.